Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06301035
Other study ID # 2024-01-012
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 18, 2024
Est. completion date December 31, 2024

Study information

Verified date March 2024
Source Samsung Medical Center
Contact Chi Ryang Chung, MD, PhD
Phone +82-2-3410-3430
Email ccrzzang@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Background The exacerbation of respiratory failure that occurs after endotracheal intubation often occurs in patients who have received mechanical ventilation therapy, and when it occurs, it emerges as an important issue to consider reintubation of endotracheal intubation. High-flow nasal cannula (HFNC) through nasal cannula is known to produce positive airway pressure and deliver a certain amount of oxygen, and recently reported clinical studies have demonstrated the effect of lowering the risk of reintubation after endotracheal intubation, which is recommended for use in recent clinical practice guidelines. However, in patients at high risk of intubation failure, the combination of high-flow oxygen therapy and non-invasive positive-pressure ventilation therapy rather than the application of high-flow oxygen therapy alone through nasal cannula is helpful in reducing the rate of reintubation of endotracheal intubation. However, an alternative to non-invasive positive-pressure ventilation therapy is needed as there is a possibility of complications such as aspiration pneumonia, maladaptation of the application device (mask), and discomfort, making it difficult to apply it in the field. Recently, it has been reported that high flow oxygen therapy through an asymmetric nasal cannula forms sufficient positive pressure in terms of respiratory dynamics, which makes the patient feel comfortable and reduces work of breath. However, no clinical studies have yet compared physiological effects using this method in patients at high risk of extubation failure. Goal The investigators would like to compare the physiological effects of high flow oxygen therapy through 'asymmetric nasal cannula' with high flow oxygen therapy through 'standard nasal cannula' in patients identified as high-risk groups for valvular failure. Hypothesis 'Asymmetric nasal cannula' reduces work of breath compared to 'standard nasal cannula' in high-risk patients with valvular failure.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date December 31, 2024
Est. primary completion date October 31, 2024
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. 19 years of age or older 2. Patients who applied mechanical ventilation treatment for more than 24 hours before the excision 3. Patients who underwent endotracheal intubation rather than tracheal incision 4. Planned extubation after successful spontaneous breathing trial (SBT) 5. Reintubation High Risk Patients: If any of the following conditions are met 1. Age > 65 2. Acute Physiology and Chronic Health Evaluation(APACHE) II on the day of extubation > 12 3. Body mass index (BMI) > 30 kg/m2 4. Inability to deal with respiratory secretions - improper cough reflex - If at least three aspirations are required in the 8 hours prior to the discharge 5. Difficult or long delay in mechanical ventilation - The first attempt to leave the mechanical ventilation failed 6. Charlson Commercial Index (CCI) at least 2 categories of comorbidities 7. Heart failure is the main indication of mechanical ventilation application 8. Moderate to severe chronic obstructive pulmonary disease 9. If there is a problem with airway openness (high risk of developing laryngeal edema) - a woman - Oral endotracheal intubation maintenance period of at least 3 days - Difficult to intubate endotracheally (difficult airway) 10. Long-term mechanical ventilation application: When applied for more than 7 days Exclusion Criteria: 1. a patient with a tracheostomy tube 2. Contraindicated application of nasal interfaces - a nasal disorder 3. Continuous positive pressure (CPAP) application contraindications - pneumothorax, blistering lung disease, head trauma, cranial facial surgery, airway foreign matter, unstable hemodynamics, etc 4. EIT application contraindications - Patients using implantable electronic medical devices (such as implantable defibrillators, pacemakers or spinal cord stimulators) - a patient with hyperhidrosis - a patient whose physical movements are not controlled - a pregnant woman - BMI 50 or higher

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Asymmetric High flow nasal cannula
Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group. The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%. After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary.
Standard(symmetric) High flow nasal cannula
Both the test group and the control group apply high flow oxygen therapy for at least 24 hours from the time of initial excretion (0h), and only the nasal interface is applied differently depending on the allocation group. The initial flow rate setting is 10 L/min, and it can be adjusted up to 50 L/min within the range where the subject does not experience discomfort. Except for cases where the patient complains of being hot, the initial temperature setting is 37°C, and the inhaled oxygen concentration (FiO2) may be adjusted to a target of 93% or more of peripheral oxygen saturation (SpO2) in the range of 21 to 100%. After 24 hours, high flow oxygen therapy is discontinued and conventional oxygen therapy can be applied if necessary.

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (2)

Lead Sponsor Collaborator
Samsung Medical Center Fisher and Paykel Healthcare

Country where clinical trial is conducted

Korea, Republic of, 

References & Publications (6)

Hernandez G, Paredes I, Moran F, Buj M, Colinas L, Rodriguez ML, Velasco A, Rodriguez P, Perez-Pedrero MJ, Suarez-Sipmann F, Canabal A, Cuena R, Blanch L, Roca O. Effect of postextubation noninvasive ventilation with active humidification vs high-flow nasal cannula on reintubation in patients at very high risk for extubation failure: a randomized trial. Intensive Care Med. 2022 Dec;48(12):1751-1759. doi: 10.1007/s00134-022-06919-3. Epub 2022 Nov 18. Erratum In: Intensive Care Med. 2023 Mar;49(3):385. — View Citation

Hernandez G, Vaquero C, Colinas L, Cuena R, Gonzalez P, Canabal A, Sanchez S, Rodriguez ML, Villasclaras A, Fernandez R. Effect of Postextubation High-Flow Nasal Cannula vs Noninvasive Ventilation on Reintubation and Postextubation Respiratory Failure in High-Risk Patients: A Randomized Clinical Trial. JAMA. 2016 Oct 18;316(15):1565-1574. doi: 10.1001/jama.2016.14194. Erratum In: JAMA. 2016 Nov 15;316(19):2047-2048. JAMA. 2017 Feb 28;317(8):858. — View Citation

Slobod D, Spinelli E, Crotti S, Lissoni A, Galazzi A, Grasselli G, Mauri T. Effects of an asymmetrical high flow nasal cannula interface in hypoxemic patients. Crit Care. 2023 Apr 18;27(1):145. doi: 10.1186/s13054-023-04441-6. — View Citation

Tan D, Walline JH, Ling B, Xu Y, Sun J, Wang B, Shan X, Wang Y, Cao P, Zhu Q, Geng P, Xu J. High-flow nasal cannula oxygen therapy versus non-invasive ventilation for chronic obstructive pulmonary disease patients after extubation: a multicenter, randomized controlled trial. Crit Care. 2020 Aug 6;24(1):489. doi: 10.1186/s13054-020-03214-9. — View Citation

Tatkov S, Rees M, Gulley A, van den Heuij LGT, Nilius G. Asymmetrical nasal high flow ventilation improves clearance of CO2 from the anatomical dead space and increases positive airway pressure. J Appl Physiol (1985). 2023 Feb 1;134(2):365-377. doi: 10.1152/japplphysiol.00692.2022. Epub 2023 Jan 12. — View Citation

Thille AW, Muller G, Gacouin A, Coudroy R, Decavele M, Sonneville R, Beloncle F, Girault C, Dangers L, Lautrette A, Cabasson S, Rouze A, Vivier E, Le Meur A, Ricard JD, Razazi K, Barberet G, Lebert C, Ehrmann S, Sabatier C, Bourenne J, Pradel G, Bailly P, Terzi N, Dellamonica J, Lacave G, Danin PE, Nanadoumgar H, Gibelin A, Zanre L, Deye N, Demoule A, Maamar A, Nay MA, Robert R, Ragot S, Frat JP; HIGH-WEAN Study Group and the REVA Research Network. Effect of Postextubation High-Flow Nasal Oxygen With Noninvasive Ventilation vs High-Flow Nasal Oxygen Alone on Reintubation Among Patients at High Risk of Extubation Failure: A Randomized Clinical Trial. JAMA. 2019 Oct 15;322(15):1465-1475. doi: 10.1001/jama.2019.14901. Erratum In: JAMA. 2020 Feb 25;323(8):793. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Respiratory Rate Oxygenation (ROX) Index Changes in Respiratory Rate Oxygenation (ROX) Index after extubation
4.88 = ROX index ; Low Risk 3.85 = ROX index < 4.88 ; Re-evaluate after 1-2 hours 3.85 > ROX index ; considerate about intubation
1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary The Lowest value of SpO2 within 24 hours after extubation Gas exchange (blood gas analysis) - The Lowest value of SpO2 within 24 hours after extubation within 24 hours after extubation
Secondary PaO2/FiO2 Gas exchange (blood gas analysis) - PaO2/FiO2 30 minutes, 6 hours, 24 hours
Secondary SpO2/FiO2 Gas exchange (blood gas analysis) - SpO2/FiO2 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary changes of end-expiratory lung impedance, at each flow rate measured through Electrical Impedance tomography (EIT) Pulmonary Dynamics (EIT) - changes of end-expiratory lung impedance, at each flow rate measured through Electrical Impedance tomography (EIT) 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary Changes in non-homogeneity indicators measured through EIT (changes in Global homeogeneity index) Pulmonary Dynamics (EIT) - Changes in non-homogeneity indicators measured through EIT (changes in Global homeogeneity index) 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary Respiratory rate respiratory capacity indicator - Respiratory rate 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary work of breath (Modified Borg Scale, MBS) respiratory capacity indicator - work of breath (Modified Borg Scale, MBS)
:The degree of work of breath is indicated by the patient himself/herself 0: Nothing at all 0.5: Very, very slight (just noticeable)
Very slight
Slight
Moderate
Somewhat severe 5,: Severe 6, 7: Very severe 8, 9: Very, very severe (almost maximal)
10: Maximal
1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary systolic blood pressure hemodynamics - systolic blood pressure 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary mean arterial pressure hemodynamics - mean arterial pressure 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary heart rate hemodynamics - heart rate 1 hour, 2 hours, 6 hours, 12 hours, 24 hours
Secondary Rate of reintubation within 7 days clinical outcomes - Rate of reintubation within 7 days within 7 days after extubation
Secondary Length of ICU stay clinical outcomes - Length of ICU stay From date of ICU admission until the date of ICU discharge, assessed up to 2 years
Secondary Length of hospital stay clinical outcomes - Length of hospital stay From date of hospital admission until the date of hospital discharge, assessed up to 2 years
Secondary ICU Mortality clinical outcomes - ICU Mortality From date of extubation until the date of ICU discharge or date of death from any cause, whichever came first, assessed up to 1 year
Secondary Hospital Mortality clinical outcomes - Hospital Mortality From date of extubation until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to 1 year
Secondary 28 Day Mortality clinical outcomes - 28 Day Mortality From date of extubation until the date of 28 Day or date of death from any cause, whichever came first, assessed up to 1 months
Secondary 90 Day Mortality clinical outcomes - 90 Day Mortality From date of extubation until the date of 90 Day or date of death from any cause, whichever came first, assessed up to 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05144633 - Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Recruiting NCT03021902 - Nutrition and Exercise in Critical Illness Phase 2
Completed NCT02902146 - Bougie Use in Emergency Airway Management N/A
Completed NCT02901158 - Esophageal Manometry in Mechanically Ventilated Patients
Completed NCT02236559 - High Flow Therapy for the Treatment of Respiratory Failure in the ED N/A
Recruiting NCT02056093 - Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist N/A
Terminated NCT01083277 - Variable Ventilation During Acute Respiratory Failure N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01462279 - Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness N/A
Completed NCT01114022 - Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane N/A
Active, not recruiting NCT01058421 - Treatment of Critical Illness Polyneuromyopathy Phase 2
Completed NCT00252616 - Timing of Target Enteral Feeding in the Mechanically Ventilated Patient Phase 2/Phase 3
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting NCT06051292 - Decremental Esophageal Catheter Filling Volume Titration For Transpulmonary Pressure Measurement N/A
Completed NCT04601090 - Survival Rates and Longterm Outcomes After COVID-19
Recruiting NCT05423301 - Global Physiotherapy in ICU Patients With High Risk Extubation Failure N/A
Completed NCT02447692 - Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study N/A
Completed NCT04016480 - HFNC During Bronchoscopy for Bronchoalveolar Lavage N/A
Completed NCT04507425 - High Flow Nasal Cannula With Noninvasive Ventilation N/A